Key Takeaways
A Phase III trial testing Arvinas’ and Pfizer’s estrogen receptor-targeting protein degrader vepdegestrant in breast cancer had mixed results.
While the trial reached the primary efficacy endpoint of PFS in estrogen receptor 1-mutant patients, it missed in the broader population, a profile in line with other oral SERDs.
Investors were disappointed by the update, with Arvinas’ stock losing more than half its value.
Hopes that Arvinas/Pfizer’s estrogen receptor-targeting protein degrader vepdegestrant will show improved efficacy in breast cancer over selective estrogen receptor degraders...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?